Biosimilars

July 10th 2023

Amgen’s Amjevita was already on the pharmacy benefit manager’s National Preferred Flex Formulary.

July 4th 2023

7 of them launched during the first several days of July, joining Amgen's Amjevita in the suddenly crowded market of Humira competitors. Pfizer’s Abrilada is the only FDA-approved Humira biosimilar that hasn’t launched.

July 1st 2023

Boehringer Ingelheim is pricing its biosimilar 5% to 7% below AbbVie’s top selling drug.

March 21st 2023

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.